Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.67 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6038270 | 0.99 | HTR6 (0.68) | HTR6HTR2CHTR2AKDM4EALOX15 | |
| SCHEMBL10080981 | 0.92 | HTR6 (0.66) | HTR6HTR2CHTR2A | |
| SCHEMBL6038265 | 0.89 | HTR6 (0.54) | HTR6HTR2CHTR2AKDM4EALOX15 | |
| Hydrochloric Acid SCHEMBL6221796 | 0.88 | HTR6 (0.55) | HTR6HTR2CHTR2AKDM4EALOX15 | |
| SCHEMBL6200394 | 0.86 | HTR6 (0.56) | HTR6HTR2CHTR2AKDM4EALOX15 | |
| SCHEMBL6197906 | 0.86 | HTR6 (0.54) | HTR6HTR2CHTR2AKDM4EALOX15 | |
| SCHEMBL6038297 | 0.85 | HTR6 (0.56) | HTR6HTR2CHTR2BCYP3A4 | |
| Hydrochloric Acid SCHEMBL6201411 | 0.85 | HTR6 (0.53) | HTR6HTR2CHTR2AKDM4EALOX15 | |
| SCHEMBL6038266 | 0.84 | HTR6 (0.84) | HTR6 | |
| SCHEMBL6038285 | 0.84 | HTR6 (0.59) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030109-B2 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-18 | — | — | US | claimed |
| EP-1196417-B8 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1196417-B1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | UPJOHN CO (US) | 2005-04-20 | — | — | EP | claimed |
| US-20040248880-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position | JACOBSEN ERIC JON (US) | 2004-12-09 | — | — | US | claimed |
| WO-2004096809-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-B]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040054170-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | JACOBSEN ERIC JON (US) | 2004-03-18 | — | — | US | claimed |
| US-20020156275-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA AND UPJOHN COMPANY | 2002-10-24 | — | — | US | claimed |
| US-6468999-B1 | TREATING ANXIETY, DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS IN HUMANS AND ANIMALS | PHARMACIA & UPJOHN COMPANY | 2002-10-22 | — | — | US | claimed |
| US-20020128475-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020111483-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY | 2002-08-15 | — | — | US | claimed |
| EP-1196417-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-17 | — | — | EP | claimed |
| WO-2001005793-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| US-7030109-B2 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1351961-B1 | SUBSTITUTED INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6921823-B2 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1196417-B8 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2002060903-A1 | SUBSTITUTED INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-06-06 | — | — | US | disclosed |
| EP-1196417-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005793-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111483-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | HTR4, HTR3C, HTR3B | HTR6 16/4885HTR2C 6/4885HTR2A 33/4885 |
| US-20040248880-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position | TPH1, HTR1A, HTR1D | HTR6 19/4885HTR2C 21/4885HTR2A 44/4885 |
| US-20040054170-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | TPH1, HTR1A, HTR1D | HTR6 19/4885HTR2C 21/4885HTR2A 44/4885 |
| US-20020156275-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | HTR4, HTR3C, HTR3B | HTR6 16/4885HTR2C 6/4885HTR2A 33/4885 |
| US-20020128475-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | HTR4, HTR3C, HTR3B | HTR6 17/4885HTR2C 7/4885HTR2A 31/4885 |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | HTR6, HTR5A, HTR2C | HTR6 1/4885HTR2C 3/4885HTR2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.